Compare · DOO vs EW
DOO vs EW
Side-by-side comparison of BRP Inc. Common Subordinate Voting Shares (DOO) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- DOO operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $52.38B, about 11.5x DOO ($4.55B).
- DOO has been more active in the news (8 items in the past 4 weeks vs 3 for EW).
- EW has more recent analyst coverage (25 ratings vs 9 for DOO).
- Company
- BRP Inc. Common Subordinate Voting Shares
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $4.55B
- $52.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 9
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest DOO
- BRP Inc. upgraded by TD Securities
- BRP Announces the Launch of BRP Financial Services
- Can-Am Elevates its 2027 3-Wheel Lineup With Major Ryker Updates Plus Spyder and Canyon Refinements
- Can-Am Unveils 2027 Side-by-Side and All-Terrain Vehicles: The Evolution of Off-Road Performance
- Can-Am Commits to the Future of Off-Road Innovation With Two Visionary Concept Builds: the Defender Prerunner and the Maverick R XRay
- Sea-Doo Revamps 2027 Lineup With Higher Horsepower, Featuring Rider-Inspired Updates and Refreshed Styles for PWC and Switch
- Sea-Doo Partners With Senna Brand to Honor Ayrton Senna's Timeless Legacy With an Exclusive Limited Edition
- BRP Will Present its Second Quarter Fiscal Year 2027 Results
- BRP Wins Four Red Dot Design Awards, Including a Prestigious "Best of the Best"
- BRP Opens Its Largest Global Distribution and Logistics Center in Saint-Philippe, Quebec
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results